| scholarly article | Q13442814 |
| P2093 | author name string | J Hou | |
| L Zhang | |||
| W F Carman | |||
| G K Lau | |||
| M Tsiang | |||
| S Yuen | |||
| S Lam | |||
| C S Gibbs | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| lamivudine | Q422631 | ||
| P304 | page(s) | 394-399 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. | |
| P478 | volume | 32 |
| Q44360573 | A mathematical model of the intracellular replication and within host evolution of hepatitis type B virus: Understanding the long time course of chronic hepatitis |
| Q39128672 | A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. |
| Q34716850 | A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection |
| Q46552168 | A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative |
| Q54238645 | Chronic hepatitis B virus and liver fibrosis: A mathematical model. |
| Q34059359 | Combination chemotherapy for hepatitis B virus: the path forward? |
| Q35594472 | Combination therapy for hepatitis B |
| Q44832669 | Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection |
| Q35422530 | Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. |
| Q45740632 | Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection? |
| Q34207450 | Current Options for the Therapy of Chronic Hepatitis B Infection |
| Q34390231 | Current pharmacotherapy for hepatitis B infection |
| Q34408879 | Current status of antiviral therapy for hepatitis B |
| Q34881918 | Dynamics of hepatitis B virus infection |
| Q34726155 | Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B |
| Q34601513 | Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. |
| Q46485581 | Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. |
| Q36474447 | Effects of Zhaoyangwan on chronic hepatitis B and posthepatic cirrhosis. |
| Q43532970 | Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients |
| Q35967369 | Emerging treatments in chronic hepatitis B. |
| Q41368968 | Ethnopharmacological Approaches for Therapy of Jaundice: Part II. Highly Used Plant Species from Acanthaceae, Euphorbiaceae, Asteraceae, Combretaceae, and Fabaceae Families. |
| Q33825842 | Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA |
| Q34519117 | Evolving therapies for the treatment of chronic hepatitis B virus infection |
| Q50585410 | Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-alpha. |
| Q35833000 | Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study |
| Q36410579 | HBV plus HCV, HCV plus HIV, HBV plus HIV. |
| Q35161920 | Hepatitis |
| Q34269640 | Hepatitis B infection in China |
| Q35210407 | Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation |
| Q34807240 | Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. |
| Q33341362 | Hepatitis B viral kinetics: a dynamic puzzle still to be resolved |
| Q35621634 | Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics |
| Q34394777 | Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management |
| Q37137539 | Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro |
| Q34683065 | Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections |
| Q35621690 | Hepatitis B virus resistance to antivirals: clinical implications and management. |
| Q44071068 | Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase |
| Q35147050 | Hepatitis C virus therapies: current treatments, targets and future perspectives |
| Q34515671 | How will we use the new antiviral agents for hepatitis B? |
| Q28345952 | In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil |
| Q34105204 | Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro |
| Q24683341 | Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials |
| Q36190663 | Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial |
| Q39400111 | Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study |
| Q46504436 | Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. |
| Q35068048 | Management of chronic hepatitis B. |
| Q33959006 | Management of viral hepatitis B. |
| Q34500227 | Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy |
| Q34521747 | Mechanisms of action of ribavirin in antiviral therapies |
| Q45722493 | Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus |
| Q47563099 | Modeling and Control of a Delayed Hepatitis B Virus Model with Incubation Period and Combination Treatment |
| Q37017548 | Modeling complex decay profiles of hepatitis B virus during antiviral therapy |
| Q36014942 | Modeling the mechanisms of acute hepatitis B virus infection |
| Q34572224 | Modelling viral and immune system dynamics |
| Q36920409 | Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a |
| Q39652342 | Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus |
| Q35543577 | Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period |
| Q51612322 | Numerical diagnoses of superinfection in chronic hepatitis B viral dynamics. |
| Q57004880 | Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response |
| Q35095217 | Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. |
| Q45388069 | Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection |
| Q44679844 | Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? |
| Q34299035 | Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation |
| Q44111343 | Specific, sensitive and accurate LC-MS/MS method for the measurement of levovirin in rat and monkey plasma |
| Q44039658 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. |
| Q33753991 | Understanding the Complex Patterns Observed during Hepatitis B Virus Therapy. |
| Q37287635 | Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy |
Search more.